Benutzer: Gast  Login
Titel:

Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.

Dokumenttyp:
Journal Article
Autor(en):
Brill, TH; Kübler, HR; von Randenborgh, H; Fend, F; Pohla, H; Breul, J; Hartung, R; Paul, R; Schendel, DJ; Gansbacher, B
Abstract:
BACKGROUND: The purpose of this vaccine study was to determine the safety and feasibility of vaccination with an allogeneic prostate carcinoma cell line, LNCaP, expressing recombinant interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) and to evaluate the efficacy of inducing tumor-specific immune responses in HLA-A2-matched patients with hormone refractory prostate cancer (HRPC). METHODS: In a dose-escalating phase I study, HLA-A2-matched HRPC patients received four vaccinations of irradiated...     »
Zeitschriftentitel:
J Gene Med
Jahr:
2007
Band / Volume:
9
Heft / Issue:
7
Seitenangaben Beitrag:
547-60
Sprache:
eng
Volltext / DOI:
doi:10.1002/jgm.1051
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/17514769
Print-ISSN:
1099-498X
TUM Einrichtung:
Institut für Allgemeine Pathologie und Pathologische Anatomie; Institut für Experimentelle Onkologie und Therapieforschung
 BibTeX